Title: Powder for reconstitution of an anti-HIV-1 drug with low water solubility - formulation development, stability and bioavailability in dogs
Authors: Van Gyseghem, Elke
Pendela, Murali Mohan
Baert, Lieven
Rosier, Jan
Van 't Klooster, Gerben
De Man, Hilde
Bouche, Marie-Paule
Schueller, Laurent
Adams, Erwin
Hoogmartens, Jos
Van den Mooter, Guy #
Issue Date: 18-Nov-2008
Conference: AAPS location:Atlanta, Georgia date:16-20 November 2008
Article number: T3143
Abstract: Purpose. To develop suspendable powders for reconstitution of the next-generation HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 with low water solubility, by using a spray-dry technology. Such powders would allow flexible dosing, e.g. on body weight basis, instead of a fixed drug amount when taking tablets. The selection of formulation excipients was based on their potential to create and maintain supersaturation solubility of the active compound in 0.01 M HCl.
Materials and methods. Suitable water-soluble carriers for TMC278 were selected by a supersaturation screening and formulated into powders for reconstitution by spray-drying. The selected powders for reconstitution were then compared to a developed tablet formulation of TMC278.HCl, in vitro using dissolution and stability testing, and in vivo through administration to beagle dogs, fed immediately after dosing.
Results. The spray-dried powders for reconstitution made up of TMC278/PVP-VA 64 1:9 (w/w) and TMC278/PVP-VA 64/Cremophor EL 1:8.5:0.5 (w/w/w) showed ease of suspendability, nearly complete dissolution of the drug substance and acceptable stability after one month storage at 25°C and 40°C. In dogs, TMC278 was more slowly absorbed from tablets than from the suspended powders for reconstitution. Compared to the tablet, the relative biovailability obtained with the powders ranged from 69 to 89% for TMC278/PVP-VA 64 1:9 (w/w) and from 85 to 157% for TMC278/PVP-VA 64/Cremophor EL 1:8.5:0.5 (w/w/w).
Conclusions. Based on in vivo and in vitro performance, both powders are suitable for future clinical use. Their advantageous in vivo behaviour and opportunity for flexible dosing provides a platform for formulations for pediatric anti-HIV therapy.
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Drug Delivery and Disposition
Pharmaceutical Analysis
# (joint) last author

Files in This Item:
File Description Status SizeFormat
AAPS 2008-abstract Elke Van Gyseghem 05052008.docAbstract poster presentation Published 22KbMicrosoft WordView/Open


All items in Lirias are protected by copyright, with all rights reserved.